Friday, 31 May 2013

New Drug from UTSW Could Offer Prostate Cancer Treatment

New Drug from UTSW Could Offer Prostate Cancer Treatment
D Healthcare Daily
Raj hopes the drug that has been tested in mouse and human tissue will lead to new treatment options and increased longevity for men diagnosed with prostate cancer. Additional testing is needed before the drug can be studied in Phase 1 clinical trials ...

 
http://healthcare.dmagazine.com/2013/05/29/new-drug-from-utsw-offers-possible-prostate-cancer-treatment/

GSK Hits Trifecta with Melanoma Drug, Dx Approvals

GSK Hits Trifecta with Melanoma Drug, Dx Approvals
Genetic Engineering News
A total 250 previously untreated adult patients with BRAF V600E mutation-positive unresectable or metastatic melanoma were randomized to either drug. Mekinist was approved after Phase III data showed a statistically significant increase in PFS, to a ...


http://www.genengnews.com/gen-news-highlights/gsk-hits-trifecta-with-melanoma-drug-dx-approvals/81248422/

Thursday, 30 May 2013

Who pays for drugs used in Phase 1 clinical trials? Clues to Cancer

Who pays for drugs used in Phase 1 clinical trials Clues to Cancer ...

When a drug is Food and Drug Administration-approved but being used to treat a cancer other than what it was originally intended for, insurance often ...

http://www.cleveland.com/healthfit/index.ssf/2013/04/who_pays_for_drugs_used_in_pha.html

PHARMA IQ-A Global Guide to Formulation and Drug Delivery

PHARMA IQ-Global Insights on Pharmaceutical Contract Manufacturing

PHARMA IQ-Five Strategies to Accelerate the Transformation of the Pharmaceutical Industry by 2020

Big Pharma Report 2011

Future Pharma

Five Strategies to Accelerate the Transformation of the Pharmaceutical Industry by 2020


DOWNLOAD HERE
http://www.pharma-iq.com/market-access/white-papers/future-pharma-five-strategies-to-accelerate-the-tr/?mac=PMIQ_SIB

Great News For Gilead Sciences And HCV Patients

Great News For Gilead Sciences And HCV PatientsSeeking AlphaGilead submitted a New Drug Application [NDA] with the same Phase 3 trial data to the FDA in April 2013. The FDA has since issued a Form 483 letter questioning the company's test procedures, stability testing and laboratory controls regarding several ...http://seekingalpha.com/article/1465861-great-news-for-gilead-sciences-and-hcv-patients?source=google_news

Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block f

Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL ...DailyFinanceWe look forward to initiating the Phase 3 portion of this trial and ultimately to providing orthopedic patients with a new option that could significantly contribute to the management of their postsurgical pain by replacing a perineural catheter, drug ...http://www.dailyfinance.com/2013/05/29/pacira-pharmaceuticals-inc-announces-positive-inte/

Is This the Beginning of the End for Alzheimer's?

Is This the Beginning of the End for Alzheimer's?Motley FoolUnfortunately, no matter how promising drugs appear in phase 2 results, they fail in phase 3 trials without slowing the progression of this debilitating neurological disease. Now, researchers at the University of Cambridge have discovered the mechanism ...
http://www.fool.com/investing/general/2013/05/29/is-this-the-beginning-of-the-end-for-alzheimers.aspx

Wednesday, 29 May 2013

Sonepcizumab/LT1009-US-based Lpath has begun patient dosing in Phase 2a single-arm trial of anti-cancer drug, Asonep.

Gilead Sciences reported that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission.

Links
http://www.allfordrugs.com/2013/05/29/gilead-sciences-reported-that-in-a-recent-phase-2-study-its-oral-drug-idelalisib-successfully-drove-the-life-threatening-chronic-lymphocytic-leukemia-cll-into-remission/
Gilead Sciences reported that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission.

Mitsubishi Tanabe seeks manufacturing, marketing approval for TA-7284, Canagliflozin in Japan

Astellas Pharma and Medivation have announced the submission of application for marketing approval of enzalutamide in Japan for the treatment of prostate cancer

TSRI develops new technique for finding therapeutic antibodies

India: new strategy to boost pharma exports

European Commission Approves Stribild, a New Single Tablet Regimen for the Treatment of HIV-1 Infection

AstraZeneca to Acquire Omthera Pharmaceuticals in $443M Deal

Top Japanese Pharmaceutical Companies and Their Pipelines 2011

Celgene sNDA of Abraxane obtains FDA priority review status

Tuesday, 28 May 2013

Sonepcizumab/LT1009-US-based Lpath has begun patient dosing in Phase 2a single-arm trial of anti-cancer drug, Asonep.

Swedish pharmaceutical company Moberg Pharma has completed enrolling patients in the ongoing Phase II trial of MOB-015 for the treatment of nail fungus (onychomycosis).

CFDA Approves Clinical Trials for Novel China AIDS Treatment, Azi Fu (Azvudine)

DRUGS-PROCESS CHEMISTRY OVERVIEW

DRUG MANUFACTURING PRESENTATION-PROCESSES

Monday, 27 May 2013

Structural Biology: Sulfonamide drugs may harm nervous systems by inhibiting an enzyme



This is a ribbon structure of an enzyme with sulfa drugs interacting with it.
 
Many sulfonamide drugs, such as sulfapyridine (pink), inhibit the enzyme sepiapterin reductase (blue), shown with a cofactor (green).
Credit: Science
Links
 

RESVERATROL AND ITS BENEFITS

Links
RESVERATROL AND ITS BENEFITS

Growing new brains with infrared light

Links

Growing new brains with infrared light

Roche wins FDA approval for novel diabetes Dx

Links

Roche wins FDA approval for novel diabetes Dx

AbbVie and Eisai Announce HUMIRA® Pre-filled Syringe Has Received Approval for the Treatment of Intestinal Behçet’s Disease in Japan

Links

AbbVie and Eisai Announce HUMIRA® Pre-filled Syringe Has Received Approval for the Treatment of Intestinal Behçet’s Disease in Japan

China’s Curative Medical to Seek CFDA Approval for ALung’s Respiratory Device

Links

China’s Curative Medical to Seek CFDA Approval for ALung’s Respiratory Device

CFDA Approves Clinical Trials for Novel China AIDS Treatment

Links
CFDA Approves Clinical Trials for Novel China AIDS Treatment

Xarelto approved for Secondary prevention in Acute Coronary Syndrome patients in Europe




shark
read all
Links


http://www.allfordrugs.com/2013/05/27/xarelto-approved-for-secondary-prevention-in-acute-coronary-syndrome-patients-in-europe/

or

http://newdrugapprovals.wordpress.com/2013/05/27/xarelto-approved-for-secondary-prevention-in-acute-coronary-syndrome-patients-in-europe/

Friday, 24 May 2013

Investigational New Drug Application Cleared by FDA for OMS824 in Huntington’s Disease

Takeda Begins Phase III Trial of Ixazomib, Multiple Myeloma Drug

Biogen submits MS drug Plegridy, peginterferon beta-1a to FDA

Breast Cancer Fighting Hormone Identified

Breast Cancer Fighting Hormone Identified

A new tumor-killer




saxs_hamlet














Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule proven to successfully kill tumor cells. This molecule is based on a natural protein present in human breast milk, which has been found to have strong and wide-ranging tumor killing properties when bound to certain lipids. Lipids are organic molecules … more…

Radioactive nanoparticles selectively target cancer cells



the nanoparticles as designed by Lewis and Robertson. The green interior depicts the radioactive lutetium surrounded by a gold shell. Credit can go to Michael Lewis, University of Missouri and Harry S. Truman Memorial Veterans’ Hospital.







Researchers at the University of Missouri have found a way to create radioactive nanoparticles that target lymphoma tumor cells wherever they may be in the body. Michael Lewis, an associate professor of oncology in the MU College of Veterinary Medicine, says being able to target secondary tumors is vital to successfully treating patients with progressive … more…

Awakening to New Drugs against Sleeping Sickness

Awakening to New Drugs against Sleeping Sickness

Structure–activity relationships and optimization of triazine nitriles as rhodesain inhibitors
Read more

New Route to Anticancer Agent Quinocarcin

 


Synthesis of quinocarcin through a convergent strategy based on Sonogashira coupling and gold(I)-catalyzed hydroamination
Read more

Hope for Hepatitis Drug

Hope for Hepatitis Drug


A straightforward synthesis of an antiviral drug, entecavir, to treat hepatitis B has industrial scale-up potential
Read more

Thursday, 23 May 2013

Scientists Uncover How Grapefruits Provide a Secret Weapon in Medical Drug Delivery

Reducing caloric intake delays nerve cell loss



(Credit: iStockphoto)

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May 22 issue of The Journal of Neuroscience. The findings could one day guide researchers to discover drug alternatives that slow … more…

Scientists sequence genome of ‘sacred lotus,’ may hold anti-aging secrets



Nelumbo nucifera from China, more commonly known as the 'sacred lotus'
(Credit: Jane Shen-Miller /UCLA)

A team of 70 scientists from the U.S., China, Australia and Japan reports having sequenced and annotated more than 86 percent of the genome of the “sacred lotus,” which is believed to have a powerful genetic system that repairs genetic defects, and may hold secrets about aging successfully. The Nelumbo nucifera plant is revered in … more…

Do salamanders hold the solution to regeneration


Do salamanders hold the solution to regeneration

401px-SpottedSalamander

Salamanders’ immune systems are key to their remarkable ability to regrow limbs, and could also underpin their ability to regenerate spinal cords, brain tissue and even parts of their hearts, scientists have found. In research published in the Proceedings of the National Academy of Sciences (open access), researchers from the Australian Regenerative Medicine Institute (ARMI) at … more…

Schizophrenia medicine works on antibiotic-resistant bacteria

File:Staphylococcus aureus VISA 2.jpg
 
Researchers have shown that the drug thioridazine,
 
 
which was once used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as Staphylococcus aureus.

Read more: http://www.digitaljournal.com/article/350622#ixzz2U5bilVl5  or